SCHEMBL2467093

SCHEMBL2467093

CC(=O)c1ccc(NC2=C(N3CCCC3)C(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APAF1 O14727 12/20 0.80
▸ MAPT P10636 11/20 0.80
▸ ALDH1A1 P00352 8/20 0.80
▸ L3MBTL1 Q9Y468 6/20 0.80
▸ GAA P10253 3/20 0.80
▸ CASP3 P42574 1/20 0.80
▸ SENP8 Q96LD8 1/20 0.80
▸ SENP7 Q9BQF6 1/20 0.80
▸ SENP6 Q9GZR1 1/20 0.80
▸ CDC25A P30304 3/20 0.76
▸ CDC25B P30305 3/20 0.76
▸ NPC1 O15118 6/20 0.70
▸ RAB9A P51151 5/20 0.70
▸ POLB P06746 5/20 0.69
▸ SMN1; SMN2 Q16637 5/20 0.69
▸ HTT P42858 5/20 0.69
▸ LMNA P02545 2/20 0.69
▸ MITF O75030 2/20 0.69
▸ KLF5 Q13887 1/20 0.69
▸ KMT2A Q03164 6/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12333609 0.88 CDC25A (0.98) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL4874221 0.84 APAF1 (0.97) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL4872810 0.84 MAPT (0.76) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL7247303 0.83 MAPT (0.97) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL5807881 0.83 APAF1 (1.00) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL7246266 0.82 CDC25A (0.73) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL16297187 0.82 APAF1 (1.00) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL7240441 0.82 MAPT (0.69) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL7242054 0.81 APAF1 (0.66) APAF1MAPTALDH1A1L3MBTL1GAA
SCHEMBL7247910 0.81 APAF1 (0.76) APAF1MAPTALDH1A1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012079032-A2 COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS TRANA DISCOVERY, INC. (US) 2012-06-14 — — WO claimed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 — — WO claimed
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 — — US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
WO-2012079032-A2 COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS TRANA DISCOVERY, INC. (US) 2012-06-14 — — WO disclosed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 APAF1 1324/4885MAPT 3443/4885ALDH1A1 2506/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 APAF1 1324/4885MAPT 3443/4885ALDH1A1 2506/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 APAF1 1324/4885MAPT 3443/4885ALDH1A1 2506/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 APAF1 1324/4885MAPT 3443/4885ALDH1A1 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback